Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beigene/Boehringer Biomanufacturing Bond Tests China MAH System

This article was originally published in PharmAsia News

Executive Summary

Nasdaq-listed BeiGene expects to need more CMO services for its clinical stage biologics following on from a clinical trials manufacturing agreement for a PD-1 antibody with Boehringer Ingelheim China, which marked the first such pilot program under China’s drug marketing authorization holder system. Shanghai is also preparing risk guarantee funds to back the pilot program, in order to promote pharmaceutical innovation.

Advertisement

Related Content

Deal Watch: From The Sidelines Of J.P. Morgan, Lots Of Discovery Deals
WuXi Biologics To Be ‘World’s No.1’ Biologics Maker

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC089354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel